Generally the big pharmaceutical industry is divided into two major segments and seven sub-sectors. Among them, the two major segments are: medical and pharmaceutical.
On the seven sub-industries, they can be divided as follows:
The ones represented by medicine can be divided into: medical services, pharmaceutical business, and medical devices.
As represented by pharmaceuticals, it can be divided into: APIs, chemical pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine.
The following is a list of leading stocks with the best performance in each sub-industry of the pharmaceutical industry.
1, chemical pharmaceutical leader: Hengrui Medicine (600276). Here will not be introduced.
2, innovative drug services leader: WuXi Kangde (603259). The company is the world's leading ? integrated, end-to-end? s new drug development service platform. From 2016 to the third quarter of 2019, the company's return on net assets was 29%, 21%, 23%, and 9.89% respectively. Revenue growth was 25%, 27%, 24%, and 34%, respectively. Net income growth was 179%, 25%, 84% and -8%, respectively.
3, medical device leader: Myriad Medical (300760). The company is the largest domestic revenue volume of medical devices listed companies, a number of production lines market share is located in the domestic TOP 3. From 2016 to the third quarter of 2019, the company's return on net assets were 28%, 47%, 42%, 22%. Operating income growth was 12%, 23%, 23%, and 20%, respectively. Net income growth is 75%, 61%, 43%, and 26%, respectively.
4, medical services leader: Aier ophthalmology (300015). The company is one of China's largest ophthalmic medical institutions, private eye hospital chain leading enterprises. From 2016 to the third quarter of 2019, the company's return on net assets were 21%, 21%, 18% and 20%. Operating income growth was 26%, 49%, 34%, and 26%, respectively. Net income growth is 30%, 33%, 35%, and 37%, respectively.
5, leading biopharmaceutical: Changchun High-tech (000661). The company's leading products, growth hormone series products and freeze-dried live attenuated varicella vaccine, have obvious competitive advantages in the market. From 2016 to the third quarter of 2019, the company's return on net assets were 15%, 16%, 20% and 21%. Operating income growth was 20%, 41%, 31%, and 31%, respectively. Net income growth is 26%, 36%, 52%, and 47%, respectively.
6, blood products leader: Hualan Bio (002007). The company is a leading enterprise in the domestic blood products and vaccine products industry. From 2016 to the third quarter of 2019, the company's return on net assets was 19%, 18%, 22%, and 16%, respectively. Operating income growth was 31%, 22%, 35%, and 29%, respectively. Net income growth was 32%, 5%, 38%, and 26%, respectively.
7, pharmaceutical business leader: Yifeng Pharmacy (603939). The company is a pharmaceutical retail chain focusing on central, southern and eastern China. From 2016 to the third quarter of 2019, the company's return on net assets were 10%, 10%, 12% and 9%. Operating income growth was 31%, 28%, 43%, and 58%, respectively. Net income growth is 27%, 40%, 32%, and 35%, respectively.
8, Chinese medicine leader: Pientzehuang (603939). Pientzehuang, the core product of the company, is honored by the domestic and foreign traditional Chinese medicine circles as ? National Treasure Famous Medicine? The company's core product Pientzehuang is honored as a national treasure and famous medicine by Chinese medicine circles at home and abroad. Chinese old brand name? From 2016 to the third quarter of 2019, the company's return on net assets is 16%, 21%, 25% and 19% respectively. Operating income growth was 22%, 60%, 28%, and 21%, respectively. Net income growth is 14%, 50%, 41%, and 20%, respectively.